Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Canadian securities regulators announce filing relief for issuers due to the coronavirus
Canada | Publication | March 19, 2020 - 9 PM ET
In response to the mounting as COVID-19 (coronavirus) crisis, the CSA announced it will provide blanket relief from certain regulatory filings required to be filed on or before June 1, 2020.
Continuous disclosure relief
The proposed relief will provide a blanket 45-day extension from existing deadlines for periodic filings required to be made by issuers on or before June 1, 2020, including annual financial statements, MD&A and annual information forms. Further details of the relief will be published shortly.
The extension applies to all issuers. For those with a December 31 year-end, the extensions are as follows:
TSX-listed issuers
| Original Deadline | New deadline | |
|---|---|---|
| Annual filing deadline (year-end financials, MD&A and AIF) | March 30 | May 14 |
| Q1 filing deadline | May 15 | June 29 |
TSX-Venture and CSE-listed issuers
| Original Deadline | New deadline | |
|---|---|---|
| Annual filing deadline (year-end financials, MD&A and AIF) | April 29 | June 15 |
| Q1 filing deadline | June 1 | July 14 |
The requirement to file a management cease-trade order, announced earlier this week, no longer applies to issuers who will miss a deadline as a result of the coronavirus, provided they comply with the soon-to-be-announced relief conditions.
The relief will allow issuers to focus on critical business decisions surrounding the virus.
Virtual shareholder meetings
In addition, the CSA has indicated it will soon be issuing guidance on annual general meetings in light of issuers considering virtual meetings to mitigate the risk of transmission of the coronavirus.
We will keep you posted as further details become available.
Recent publications
Publication
Country risk in unprecedented times: A precedent for cross-border loan documentation?
While country risk cannot be avoided in cross-border transactions entirely, it can be effectively mitigated through careful transaction structuring and tailored contractual protections.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .